Literature DB >> 7587259

Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome.

S Gando1, Y Nakanishi, I Tedo.   

Abstract

OBJECTIVES: a) To investigate the relationships between tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), plasminogen activator inhibitor-1, and disseminated intravascular coagulation (DIC); b) to determine the influence of DIC on the mortality rate, adult respiratory distress syndrome (ARDS), and multiple organ dysfunction syndrome; and c) to find a useful prognostic index for outcome.
DESIGN: Prospective, case-control study.
SETTING: General intensive care unit (tertiary care center) in a city hospital serving a population of 1.5 million people. PATIENTS: Fifty-eight trauma patients; 22 of the patients with DIC and 36 of the patients without DIC.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: TNF-alpha, IL-1 beta, plasminogen activator inhibitor-1 activity, and plasminogen activator inhibitor-1 antigen concentration were measured on the day of the injury, and on days 1, 3, and 5 after admission. The results of these measurements, demographic data, severity of illness score, mortality rate in the intensive care unit and frequencies of ARDS, multiple organ dysfunction syndrome, and sepsis were compared according to the occurrence of DIC. DIC patients were classified into subgroups of survivors and nonsurvivors, and the changes in plasminogen activator inhibitor-1 between subgroups were studied. The Acute Physiology and Chronic Health Evaluation II scores, the Injury Severity Scores, and the frequency of ARDS and multiple organ dysfunction syndrome were higher in the DIC patients. The mortality rate of the DIC patients was higher than the rate of the non-DIC patients (59.0% vs. 13.8%; p = .0009). TNF-alpha and IL-1 beta concentrations increased more in the DIC patients than in the non-DIC patients. Plasminogen activator inhibitor-1 activity and plasminogen activator inhibitor-1 antigen concentrations in the DIC patients, especially those values in the nonsurvivors, continued to be markedly high up to day 5 of admission. The most favorable prognostic value of plasminogen activator inhibitor-1 for the prediction of death in all of the trauma patients and the DIC patients was determined on days 3 and 5, respectively. No significant correlation was noted between the two cytokines and plasminogen activator inhibitor-1.
CONCLUSIONS: In the patients with trauma, DIC is a predictor of ARDS, multiple organ dysfunction syndrome, and death. TNF-alpha and IL-1 beta might be one of the causes of DIC, while plasminogen activator inhibitor-1 may be one of the aggravating factors of ARDS and multiple organ dysfunction syndrome. Plasminogen activator inhibitor-1 is a good predictor of death for posttrauma DIC patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7587259     DOI: 10.1097/00003246-199511000-00009

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  27 in total

1.  Femoral nailing-related coagulopathy determined by first-hit magnitude: an animal study.

Authors:  Peter V Giannoudis; Martijn van Griensven; Frank Hildebrand; Christian Krettek; Hans-Christoph Pape
Journal:  Clin Orthop Relat Res       Date:  2008-01-10       Impact factor: 4.176

2.  High fibrin/fibrinogen degradation product to fibrinogen ratio is associated with 28-day mortality and massive transfusion in severe trauma.

Authors:  D H Lee; B K Lee; S M Noh; Y S Cho
Journal:  Eur J Trauma Emerg Surg       Date:  2017-09-18       Impact factor: 3.693

Review 3.  Coagulopathy in traumatic brain injury.

Authors:  Sherman C Stein; Douglas H Smith
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

4.  Thrombin Provokes Degranulation of Platelet α-Granules Leading to the Release of Active Plasminogen Activator Inhibitor-1 (PAI-1).

Authors:  Benjamin R Huebner; Ernest E Moore; Hunter B Moore; Gregory R Stettler; Geoffrey R Nunns; Peter Lawson; Angela Sauaia; Marguerite Kelher; Anirban Banerjee; Christopher C Silliman
Journal:  Shock       Date:  2018-12       Impact factor: 3.454

5.  Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation.

Authors:  Seiji Madoiwa; Shin Nunomiya; Tomoko Ono; Yuichi Shintani; Tsukasa Ohmori; Jun Mimuro; Yoichi Sakata
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

6.  Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time.

Authors:  Myung S Park; Wenjun Z Martini; Michael A Dubick; Jose Salinas; Saulius Butenas; Bijan S Kheirabadi; Anthony E Pusateri; Jeffrey A Vos; Charles H Guymon; Steven E Wolf; Kenneth G Mann; John B Holcomb
Journal:  J Trauma       Date:  2009-08

Review 7.  Coagulopathy associated with traumatic brain injury.

Authors:  Monisha A Kumar
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

8.  A Review of Radiation-Induced Coagulopathy and New Findings to Support Potential Prevention Strategies and Treatments.

Authors:  Ann R Kennedy; Amit Maity; Jenine K Sanzari
Journal:  Radiat Res       Date:  2016-07-26       Impact factor: 2.841

9.  Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy.

Authors:  Hunter B Moore; Ernest E Moore; Eduardo Gonzalez; Michael P Chapman; Theresa L Chin; Christopher C Silliman; Anirban Banerjee; Angela Sauaia
Journal:  J Trauma Acute Care Surg       Date:  2014-12       Impact factor: 3.313

10.  Early down-regulation of the pro-inflammatory potential of monocytes is correlated to organ dysfunction in patients after severe multiple injury: a cohort study.

Authors:  Chlodwig Kirchhoff; Peter Biberthaler; Wolf E Mutschler; Eugen Faist; Marianne Jochum; Siegfried Zedler
Journal:  Crit Care       Date:  2009-06-11       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.